CompletedPhase 4

Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA

United States210 participantsStarted 2015-09-24

Plain-language summary

The purpose of this study is to study the benefits and risks of etanercept withdrawal in patients who have achieved a significant clinical response.

Who can participate

Age range18 Years – 49 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * diagnosis of axial SpA duration of symptoms \>3 months and \<5 years back pain with a less than favorable response to NSAIDs Exclusion Criteria: * radiological sacroiliitis previous treatment with TNF inhibitor, biologic, immunosuppressive

What they're measuring

Percentage of Participants Who Experienced Flare Within 40 Weeks Following Withdrawal of 24 Weeks of Etanercept Treatment

Timeframe: Within 40 weeks after Etanercept withdrawal (from Week 24 to Week 64)

Trial details

NCT IDNCT02509026

SponsorPfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2019-05-28

Results submitted2020-05-07

View on ClinicalTrials.gov More Spondylitis, Ankylosing trials